Trademark: 77858442
Word
BTG
Status Date
Thursday, June 24, 2021
Registration Number
3859364
Registration Date
Tuesday, October 12, 2010
Filing Date
Tuesday, October 27, 2009
Published for Opposition
Tuesday, July 27, 2010
5 Pharmaceutical and medicinal preparations and substances namely, vaccines and vaccine adjuvants, proteins, peptides, sera containing polyclonal antibodies and fragments thereof and polyclonal antibodies and fragments derived therefrom all for use in treating snake envenomation, overdose of toxic substances or sepsis; pharmaceutical preparations and substances for the treatment of thrombosis, [ inflammation, autoimmune disease and sleep disorders; dietetic foods adapted for medical use; ] vaccines; sera; polyclonal antibodies and fragments thereof for in vitro disease testing and for use in treating snake envenomation, overdose of toxic substances or sepsis; pharmaceutical preparations in the form of foams or for use in producing foams for use in sclerotherapy, phlebology, angiology and proctology, for treatment of oesophageal varices, hydroceles, in sterilisation treatment or for treatment of varicose veins or arteriovenous malformations; chemical reagents for medical or veterinary purposes; chemical reagents for therapeutic and diagnostic purposes, namely, for the treatment of and the diagnosis of the presence of toxic substances; pharmaceutical preparations for the treatment of cancer; [ pharmaceutical preparations for the reduction or elimination of circulating cytokines; pharmaceutical preparations for the treatment of neurodegeneration and multiple sclerosis; pharmaceutical preparations for the treatment of pain, including headache and migraine; ] pharmaceutical preparations for promoting the healing of dermal wounds and chronic wounds including ulcers and pressure sores; pharmaceutical and veterinary preparations for the treatment of digoxin, digitalis or other cardio-active glycoside toxicity; pharmaceutical preparations for the treatment of envenomation with snake venom; pharmaceutical preparations for treatment of excess levels of cancer agents; pharmaceutical preparations for the treatment of toxic levels of other pharmaceutical agents; pharmaceutical preparations for the treatment of cytotoxic cancer treatment drug overdose, particularly overdose with methotrexate; [ pharmaceutical preparations for the treatment of sleep apnea; pharmaceutical preparations for the treatment of head lice; ] diagnostic reagents for medical use and for the determination of levels of toxic substances in blood and tissue samples in vitro
1 [ Chemicals used in science; chemicals for clinical research use; diagnostic reagents and substances for clinical and medical laboratory use; diagnostic reagents and substances for clinical and medical laboratory in vitro research use; polyclonal antibodies and fragments thereof for clinical research use; diagnostic reagents and substances for in vivo clinical and laboratory research use; chemical reagents for scientific research use; chemicals used in science and medicine, namely, adjuvant compositions for use in the manufacture of vaccines and antibodies and antibody fragments for use in diagnostics and assays; cell lines for use in production of whole cell derived vaccines; cell lines for use in research related to virus mediated disease ]
10 Surgical apparatus for the treatment of varicose veins; medical syringes; cannula needles, medical tubing for administering drugs; surgical and medical apparatus for producing and administering pharmaceutical foams; surgical or medical apparatus for producing foams for treatment of varicose veins, arterio-venous malformations, oesophageal varices or hydroceles; devices for intravenous administration of pharmaceutical foam; diagnostic devices for grading the severity of venous conditions, snake envenomation and toxic drugs overdose
42 [ Product research and development, namely, development of pharmaceuticals and medical devices through preclinical and clinical research in the fields of envenomation, drug overdose, chemical poisoning, venous disease, autoimmune disease, pain and inflammation and cancer therapy ]
The mark consists of a circle with four lines inside of it; below the circle are the letters "BTG" in stylized lettering.
Color is not claimed as a feature of the mark.
Jul 13, 2023
Teas Change Of Correspondence Received
Jul 13, 2023
Attorney/Dom.Rep.Revoked And/Or Appointed
Jul 13, 2023
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Mar 16, 2023
Applicant/Correspondence Changes (Non-Responsive) Entered
Mar 16, 2023
Teas Change Of Correspondence Received
Mar 16, 2023
Attorney/Dom.Rep.Revoked And/Or Appointed
Mar 16, 2023
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Mar 16, 2023
Teas Change Of Owner Address Received
Apr 12, 2022
Applicant/Correspondence Changes (Non-Responsive) Entered
Apr 12, 2022
Teas Change Of Correspondence Received
Apr 12, 2022
Teas Change Of Domestic Representatives Address
Apr 12, 2022
Attorney/Dom.Rep.Revoked And/Or Appointed
Apr 12, 2022
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Apr 12, 2022
Teas Change Of Owner Address Received
Aug 30, 2021
Applicant/Correspondence Changes (Non-Responsive) Entered
Aug 30, 2021
Teas Change Of Correspondence Received
Aug 30, 2021
Attorney/Dom.Rep.Revoked And/Or Appointed
Aug 30, 2021
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Aug 30, 2021
Teas Change Of Owner Address Received
Jun 24, 2021
Notice Of Acceptance Of Sec. 8 & 9 - E-Mailed
Jun 24, 2021
Registered And Renewed (First Renewal - 10 Yrs)
Jun 24, 2021
Registered - Sec. 8 (10-Yr) Accepted/Sec. 9 Granted
Jun 22, 2021
Teas Response To Office Action-Post Reg Received
Jun 9, 2021
Post Registration Action Mailed - Sec. 8 & 9
Apr 14, 2021
Automatic Update Of Assignment Of Ownership
Apr 9, 2021
Teas Section 8 & 9 Received
Aug 29, 2020
Applicant/Correspondence Changes (Non-Responsive) Entered
Aug 29, 2020
Teas Change Of Correspondence Received
Aug 29, 2020
Attorney/Dom.Rep.Revoked And/Or Appointed
Aug 29, 2020
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Aug 29, 2020
Teas Change Of Owner Address Received
Oct 12, 2019
Courtesy Reminder - Sec. 8 (10-Yr)/Sec. 9 E-Mailed
Apr 21, 2017
Notice Of Acceptance Of Sec. 8 - E-Mailed
Apr 21, 2017
Registered - Partial Sec. 8 (6-Yr) Accepted
Apr 21, 2017
Case Assigned To Post Registration Paralegal
Apr 5, 2017
Teas Section 8 Received
Apr 5, 2017
Teas Change Of Correspondence Received
Oct 12, 2015
Courtesy Reminder - Sec. 8 (6-Yr) E-Mailed
Jan 15, 2014
Attorney/Dom.Rep.Revoked And/Or Appointed
Jan 15, 2014
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Apr 14, 2011
Teas Change Of Correspondence Received
Apr 6, 2011
Teas Change Of Correspondence Received
Oct 12, 2010
Registered-Principal Register
Jul 27, 2010
Official Gazette Publication Confirmation E-Mailed
Jul 27, 2010
Published For Opposition
Jun 22, 2010
Law Office Publication Review Completed
Jun 21, 2010
Assigned To Lie
Jun 4, 2010
Approved For Pub - Principal Register
May 28, 2010
Teas/Email Correspondence Entered
May 28, 2010
Correspondence Received In Law Office
May 28, 2010
Teas Response To Office Action Received
May 26, 2010
Notification Of Priority Action E-Mailed
May 26, 2010
Priority Action E-Mailed
May 26, 2010
Priority Action Written
May 7, 2010
Teas/Email Correspondence Entered
May 7, 2010
Correspondence Received In Law Office
May 7, 2010
Teas Response To Suspension Inquiry Received
Apr 21, 2010
Notification Of Letter Of Suspension E-Mailed
Apr 21, 2010
Letter Of Suspension E-Mailed
Apr 21, 2010
Suspension Letter Written
Mar 31, 2010
Teas/Email Correspondence Entered
Mar 31, 2010
Correspondence Received In Law Office
Mar 31, 2010
Teas Response To Office Action Received
Feb 1, 2010
Notification Of Non-Final Action E-Mailed
Feb 1, 2010
Non-Final Action E-Mailed
Feb 1, 2010
Non-Final Action Written
Feb 1, 2010
Assigned To Examiner
Oct 31, 2009
Notice Of Design Search Code Mailed
Oct 30, 2009
New Application Office Supplied Data Entered
Oct 30, 2009
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
